

Supporting Information

For

Practical Asymmetric Synthesis of Sitagliptin Phosphate Monohydrate

Hao-ling Gao^{1,2}, Jian-gang Yu¹, Cheng-sheng Ge^{*1,2}, Qun Jiang²

¹ College of Chemistry and Materials Engineering, Quzhou University, Quzhou 324000, China

² College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, China

* Correspondence: gechengsheng@qzu.zj.cn




Figure S1 ¹H NMR spectrum (400 MHz, 297 K, CDCl₃) of compound **1a**




Figure S2 ¹H NMR spectrum (400 MHz, 297 K, CDCl₃) of compound **1b**




Figure S3 ^1H NMR spectrum (400 MHz, 297 K, CDCl_3) of compound **3**




Figure S4 $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum (100 MHz, 297 K, CDCl_3) of compound **3**




Figure S5 ^1H NMR spectrum (400 MHz, 297 K, CDCl_3) of compound **4a**




Figure S6 $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum (100 MHz, 297 K, CDCl_3) of compound **4a**




Figure S7 ^1H NMR spectrum (400 MHz, 297 K, CDCl_3) of compound **4a**




Figure S8 $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum (100 MHz, 297 K, CDCl_3) of compound **4a**




Figure S9 ^1H NMR spectrum (400 MHz, 297 K, CDCl_3) of compound **4b**




Figure S10 $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum (100 MHz, 297 K, CDCl_3) of compound **4b**




Figure S11 ^1H NMR spectrum (400 MHz, 297 K, CDCl_3) of compound **5**




Figure S12 ^1H NMR spectrum (400 MHz, 297 K, CDCl_3) of compound **7a**






Figure S13 ^1H NMR spectrum (400 MHz, 297 K, CDCl_3) of compound **7b**

HPLC analysis





HPLC condition: Chiralcel OD-H column, 1.0 mL/min, 5% i-PrOH/Hexane, 210 nm, $t_{\text{minor}} = 6.66$ min, $t_{\text{major}} = 6.00$ min.

Racemic **3a**




(3R,5S)-tert-butyl 3-benzyl-5-hydroxyisoxazolidine-2-carboxylate (**3a**) with 92% ee







HPLC condition: Chiralcel AD-H column, 1.0 mL/min, 5% i-PrOH/Hexane, 210 nm, $t_{\text{minor}} = 11.02$ min, $t_{\text{major}} = 9.30$ min.

Racemic **3j**




(3*R*,5*S*)-tert-butyl 5-hydroxy-3-(2,4,5-trifluorobenzyl)isoxazolidine-2-carboxylate (**3j**) with 96% ee







HPLC condition: Chiralcel AD-H column, 1.0 mL/min, 5% i-PrOH/Hexane, 210 nm, $t_{\text{minor}} = 10.02$ min, $t_{\text{major}} = 8.08$ min.

Racemic **4**




(3R)-tert-butyl 3-benzyl-5-(tert-butoxycarbonyloxy)isoxazolidine-2-carboxylate (**4**) with 43% ee






HPLC condition: Chiralpak IC-3 column, 0.5 mL/min, 5% i-PrOH/Hexane, 210 nm, $t_{\text{minor}} = 21.12$ min, $t_{\text{major}} = 19.10$ min.

Racemic sitagliptin phosphate monohydrate



210nm					
entry	time	area	height	concentration	area%
1	19.109	8067455	406275	49.974	49.974
2	21.126	8075849	394571	50.035	50.035

Sitagliptin phosphate monohydrate with >99.9% ee



210nm					
entry	time	area	height	concentration	area%
1	19.114	39661070	2141580	100.000	100.000